In 2025, the net profit of WUXI XDC (02268) doubled. The adjusted net profit attributable to owners of the company is approximately 15.59 billion yuan, an increase of 69.9% year-on-year.

WUXI XDC (02268) announced its performance for 2025, with revenue of approximately 5.944 billion yuan, a year-on-year increase of 46.7%; gross profit of approximately 2.139 billion yuan, a year-on-year increase of 72.5%; adjusted net profit attributable to owners of the company of approximately 1.559 billion yuan, a year-on-year increase of 69.9%; and net profit increased by 38.4% year-on-year to 1.48 billion yuan. The total amount of unfinished orders for the group also increased by 50.3% from 991 million US dollars as of December 31, 2024 to 1.489 billion US dollars as of December 31, 2025. The announcement stated that the group's CRDMO business continued to show strong momentum in 2024 and 2025, with the business expanding actively and global customers increasing their demand for its services. As of December 31, 2025, with its comprehensive CRDMO capabilities and facilities equipped with "one-stop" functions from drug discovery to commercialization, the group has empowered a total of 643 customers worldwide by providing comprehensive services. The group has successfully obtained 18 PPQ (Process Validation) projects and 1 commercialization project. The increase in revenue is mainly due to (i) the continued active development of the global antibody-drug conjugate (ADC) and broader biologic drug conjugate markets, which has driven an increase in the number of customers and projects; (ii) the group's solid position as a leading ADCCRDMO service provider, driving an increase in its market share; and (iii) the steady progress of the group's projects to later stages (which usually generate higher contract values).